Focus Partners Wealth
IMUX icon

Focus Partners Wealth’s Immunic IMUX Stock Holding History

Focus Partners Wealth’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-262,246
Closed -$2.29M – 2741
2025
Q4 		$2.29M Buy
262,246
+4,087
+2% +$29.9K ﹤0.01% 1264
2025
Q3 		$2.28M Buy
258,159
+3,907
+2% +$34.5K ﹤0.01% 975
2025
Q2 		$1.77M Sell
254,252
-4,094
-2% -$37.6K ﹤0.01% 938
2025
Q1 		$2.82M Buy
258,346
+41,511
+19% +$448K 0.01% 767
2024
Q4 		$2.17M Buy
216,835
+2,361
+1% +$29.7K 0.01% 810
2024
Q3 		$3.54M Buy
+214,474
New +$3.05M 0.01% 643

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Focus Partners Wealth's IMUX Position: Q1 2026 in Review

Focus Partners Wealth sold out of Immunic (IMUX) in Q1 2026, closing a stake of 262,246 shares — an estimated $2.29M sold.

Focus Partners Wealth first reported a position in IMUX in Q3 2024 and held it in 6 quarters. The position peaked at $3.54M in Q3 2024. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Focus Partners Wealth reported no remaining Immunic position as of Q1 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 262,246 Immunic shares in Q1 2026, an estimated $2.29M.
  • Focus Partners Wealth first reported a position in Immunic in Q3 2024 and held it in 6 quarters.
  • Focus Partners Wealth's Immunic position peaked at $3.54M in Q3 2024.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.